🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

If your #radonc colleague covers your adaptive MR-guided SBRT case, how will their contours differ from yours❓ Covering physicians are ✅less likely to make adjustments to the gross tumor volume ✅more likely to have larger lymph node volumes advancesradonc.org/article/S2452-…

As if we weren't already ⭐️star-struck 🤩enough by the work Aadel Chaudhuri, MD PhD does... he was just (oh-so-deservingly!) promoted to 📜Professor of Radiation Oncology! Congratulations, Dr. Chaudhuri! We are so proud to have you in the Mayo Clinic family!

REPRESENTATION MATTERS! Study finds that members of NCCN committees include: 48%- med onc 21%- surg onc 9%- rad onc (3% Chair; 23% VC) Emphasizes opportunity for growth as specialty inclusivity is critical to balance diversity of perspectives in management recommendations

📢Hear ye, hear ye!👂We want to see what 🫵you've been up in the benign disease space! Submit your latest work on Radiation Indications for Non-Malignant Conditions by November 3, 2025. Questions❔DM us! advancesradonc.org/pb-assets/Heal…

Wow. This is going to start some serious debating. 🔥🔥🔥 Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy ⁦JAMA Oncology⁩ ⁦Jeff Matthews MD⁩ ⁦Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸⁩ ⁦Julio Mayol⁩ ⁦ jamanetwork.com/journals/jamao…

In this new #RedJournal article, @dawin11g7 Mayo Clinic Radiation Oncology et al discuss how minibeam RT is an innovative strategy to improve normal tissue sparing. The work demonstrates that the valley dose determines acute and late radiation effects in a mouse model. tinyurl.com/redgrams

RACE-GB, the first ever phase 3 randomized study showing overall survival improvement from chemotherapy combined with #radiation for gallbladder cancer. Accompanying podcast for context. Podcast: redjournal.org/audio-do/red-j… Article: redjournal.org/article/S0360-…

Intraop RT can be useful to reduce risk of local recurrence, particularly w/ re-RT and/or radioresistant tumors. But, there is limited availability/tech/expertise to implement Study reports on the CivaSheet, a bioabsorbable polymer sheet with unidirectionally shielded Pd-103

Anal Cancer 101 video! Treatment for anal cancer relatively straightforward for most, but several nuances (i.e. anal margin, etc) & trials coming down pipeline aiming to better tailor care to stage/biology. I review in this 17 min video. Full video link & slides below 🧵. 1/6

🚨Calling all future Rad Oncs!🚨 Interested in a visiting med student rotation at Mayo Clinic, Rochester, MN, June-Sept ❓ ☀️ Come see what we're all about—cutting-edge tech, amazing mentors, and the best resident group! Submit your application today! #RadOnc #MedTwitter #VMS

🚨CAO/ARO/AIO-12 + OPRA Rectal trials🚨 WW vs. Planned surgery after TNT for rectal Ca 🟰 OS, DFS, DM ‼️Comparable outcomes when matched for response (cCR vs. pCR, etc) 🙌Supports WW as a highly appropriate, pt-centric, option for patients with cCR after TNT

💭Whether or not you believe in adverse radiation effect (ARE) after pre-op SRS, why deliver high doses to brain lesions when you can get away with less? This group found no difference in 2-year ✅cavity local recurrence ✅ARE ✅nodular leptomeningeal disease ✅OS between

I’m SO delighted to finally see the STAR-TREC data reported 🤩 #ESTRO25 Short course RT vs chemorad for organ preservation in early stage rectal cancer 61% vs 80% TME-free survival at 12 months ➡️ More organ preservation with long-course chemorad! #radonc #rectalcancer

PLATO ACT 4: Ph II RCT of 50.4 vs. 41.4 Gy for T1-2 (<4 cm) N0 anal SCC. No difference in 3-year local recurrence (primary endpoint) or OS, & better toxicity/QOL with dose-reduction. Should 41.4 Gy be a SOC option (ahead of Ph III DECREASE trial reporting)? #ESTRO25

👏Congratulations to Mayo Clinic's #ASCO25 Featured Voices! Drs. Krishan Jethwa, radiation oncologist, and Andrea Anampa-Guzmán (she/ella), clinical pharma. fellow in oncology, will soon begin their ASCO Annual Meeting coverage. ➡️Follow them on X, LinkedIn and Bluesky to stay up to date.

Congratulations, everyone, on being recognized as featured voices for the 2025 ASCO Annual Meeting! We look forward to your expert insights and perspectives during #ASCO25. #LARVOL #CancerResearch #Oncology #OncologyInsights #ClinicalOncology #CancerData #CancerCare |

Reclassifying each N category 1 stratum higher for imaging-detected extranodal extension-positive disease resulted in better disease-free and overall survival in patients human papillomavirus–positive oropharyngeal carcinoma. ja.ma/4k0TANm Melvin LK CHUA | FRCR, PhD, FASCO

We wrote a LTE (led by Krishan Jethwa) re: some of the limitations of this study, including baseline differences in comparison groups, imperfect correlation b/w cCR and pCR - both which would bias the surgical cohort toward better outcomes.

Join us for an engaging session on POLICY at #ASCO25 on May 31, 4-6 pm, room S103 — diverse policy discussions- ✅AI / Policy ✅community onc/policy ✅advocacy/policy as an IMG Oncologists ✅policy in rural cancer care ✅policy in Telemedicine ✅research funding ✅global

✨ Practice-changing for gallbladder cancer? A randomized phase 3 trial from 🇮🇳 evaluated NACTRT vs NACT in locally advanced GBC (T3/T4, N1, liver infiltration). Results: ✂️ R0 resection: 51.6% (NACTRT) vs 29.7% (NACT) p=0.01 ⏳ Median OS: 21.8 vs 10.1 mo HR: 0.56 (95% CI